Clinical relevance of ischemic preconditioning

Scandinavian Cardiovascular Journal

Volumn 35, Issue 6, 2001, Pages 359-365

  Ylitalo, Kari ^a   Peuhkurinen, Keijo ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Human heart; Myocardial ischemia; Preconditioning

Indexed keywords

ADENOSINE A1 RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE RECEPTOR; ADENOSINE TRIPHOSPHATE; ALPHA 1B ADRENERGIC RECEPTOR; BAMIFYLLINE; BRADYKININ; BRADYKININ B2 RECEPTOR; CAPTOPRIL; DIACYLGLYCEROL; GLIBENCLAMIDE; HEAT SHOCK PROTEIN; NICORANDIL; PHOSPHOLIPASE C; PHOSPHOLIPASE D; POTASSIUM CHANNEL; PROTEIN KINASE C EPSILON; PROTEIN TYROSINE KINASE; SULFONYLUREA DERIVATIVE; THEOPHYLLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; CELL DEATH; CELL KINETICS; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DILATATION; EXPERIMENTAL ANIMAL; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MEDICAL RESEARCH; MITOCHONDRION; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; RABBIT; RECEPTOR UPREGULATION; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION;

ADAPTATION, PHYSIOLOGICAL; ANGINA, UNSTABLE; ANIMALS; CORONARY CIRCULATION; EXERCISE TEST; HUMANS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MYOCARDIAL ISCHEMIA;

EID: 0035691357     PISSN: 14017431     EISSN: None     Source Type: Journal    
DOI: 10.1080/14017430152754835     Document Type: Review

References (98)

1. Preconditioning with ischemia A delay of lethal cell injury in ischemic myocardium
2. Ischemic preconditioning decreases apoptosis in rat hearts in vivo
3. Ischemic preconditioning slows energy metabolism and delays ultrastructural damage during a sustained ischemic episode
4. Preconditioning of ischemic myocardium: Reperfusion induced arrhythmias
5. Ischaemic preconditioning in a model of global ischaemia: Infarct size limitation, but no reduction of stunning
6. Coronary vascular endothelium myocyte interactions in protection of the heart by ischaemic preconditioning
7. Repeated cardiac pacing extends the time during which canine hearts are protected against ischaemia induced arrhythmias: Role of nitric oxide
8. Proarrhythmic effects of ischemic preconditioning in anesthetized pigs
9. The role of nitric oxide in modulating ischaemia induced arrhythmias in rats
10. Preconditioning reduces infarct size but accelerates time to ventricular fibrillation in ischemic pig heart
11. Suppression of reperfusion arrhythmia by ischemic preconditioning in the rat: Is it mediated by the adenosine receptor, prostaglandin, or bradykinin receptor?
12. A "second window of protection" or delayed preconditioning phenomenon: Future horizons for myocardial protection?
13. Evidence that the adenosine A3 receptor may mediate the protection afforded by preconditioning in isolated rabbit heart
14. Pretreatment with angiotensin II activates protein kinase C and limits myocardial infarction in isolated rabbit hearts
15. Catecholamines can induce adenosine receptor-mediated protection of the myocardium but do not participate in ischemic preconditioning in the rabbit
16. Role of bradykinin in protection of ischemic preconditioning in rabbit hearts
17. Ischemic preconditioning is mediated by a peripheral opioid receptor mechanism in the intact rat heart
18. + channel in mediating the effects of acetylcholine to mimic preconditioning in dogs
19. ATP channels in the isolated rat heart
20. Phosphorylation of tyrosine 182 of p38 mitogen-activated protein kinase correlates with the protection of preconditioning in the rabbit heart
21. Role of p38 MAP kinase in myocardial stress
22. PKC-dependent activation of p44/p42 MAPKs during myocardial ischemia-reperfusion in conscious rabbits
23. Importance of PKC and tyrosine kinase in single or multiple cycles of preconditioning in rat hearts
24. Ischemic preconditioning slows energy metabolism and delays ultrastructural damage during a sustained ischemic episode
25. Mechanism of preconditioning. Ionic alterations
26. Myocardial K(ATP) channels in preconditioning
27. Cardioprotective effect of diazoxide and its interaction with mitochondrial ATP-sensitive channels. Possible mechanism of cardioprotection
28. ATP channel induces early and delayed cardioprotective effect: Role of nitric oxide
29. Intracellular free calcium and mitochondrial membrane potential in ischemia/reperfusion and preconditioning
30. 0-ATPase
31. Nuclear factor-kB plays an essential role in the late phase of ischemic preconditioning in conscious rabbits
32. Possibilities for pharmacological exploitation of ischaemic preconditioning
33. + channel
34. Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited
35. Preconditioning human ventricular cardiomyocytes with brief periods of simulated ischaemia
36. + channel
37. Preconditioning in isolated superfused human muscle
38. Mechanisms of cardiac pain during coronary angioplasty
39. + channel blocker
40. Effects of A1 adenosine receptor blockade by bamiphylline on ischemic preconditioning during coronary angioplasty
41. Improved myocardial ischemic response and enhanced collateral circulation with long repetitive coronary occlusion during angioplasty: A prospective study
42. Preconditioning of human myocardium with adenosine during coronary angioplasty
43. Bradykinin induced preconditioning in patients undergoing coronary angioplasty
44. Balloon occlusion during coronary angioplasty as a, model of myocardial ischaemia: Reproducibility of sequential inflations
45. Adaptation to ischemia during percutaneous transluminal coronary angioplasty. Clinical, hemodynamic, and metabolic features
46. Three minute, but not one minute, ischemia and nicorandil have a preconditioning effect in patients with coronary artery disease
47. Beneficial impact of preconditioning during PTCA on creatine kinase release
48. Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide
49. Repeated coronary artery occlusions during routine balloon angioplasty do not induce myocardial preconditioning in humans
50. No evidence for ischemic preconditioning during repeated vessel occlusion in coronary angioplasty
51. ST segment voltage during sequential coronary occlusion is an unreliable marker of preconditioning
52. Medical transactions of the collage physicians. As quoted by Lewis T. Pain in muscular ischemia
53. Adaptation to the stress of tachycardia in patients with coronary artery disease: Insight into the mechanisms of the warm-up phenomenon
54. Observations on the warm-up phenomenon in angina pectoris
55. Evidence suggesting coronary vasodilatation as the principal mechanism in the warm-up phenomenon
56. Attenuation of increased regional myocardial oxygen consumption during exercise as a major cause of warm-up phenomenon
57. Cellular source and role of adenosine in isoprotenol-induced coronary vasodilatation
58. Is warm-up in angina ischaemic preconditioning
59. Adaptation to myocardial ischemia during repeated dynamic exercise in relation to findings at cardiac catheterization
60. Adaptation to myocardial ischemia during repeated ventricular pacing in patients with coronary artery disease
61. Attenuation of severity of myocardial ischemia during repeated daily ischemic episodes
62. Effect of ischemic preconditioning on interstitial purine metabolites and lactate accumulation during myocardial ischemia
63. Effects of intravenous theophylline on exercise-induced myocardial ischemia. I. Impact on the ischemic threshold
64. Effect of theophylline on the warm-up phenomenon
65. Effects of K(ATP) channel blockade by glibenclamide on the warm-up phenomenon
66. Blockade of K(ATP) channels with glibenclamide does not abolish preconditioning during demand ischemia
67. Preconditioning the human myocardium
68. Ischaemic preconditioning reduces troponin T release in patients undergoing coronary artery bypass surgery
69. Normothermic retrograde blood cardioplegia with or without preceding ischemic preconditioning
70. Ischemic preconditioning prior to myocardial protection with cold blood cardioplegia in coronary surgery
71. Prospective, randomized clinical study of ischemic preconditioning as an adjunct to intermittent cold blood cardioplegia
72. Ischemic preconditioning in cardiac surgery: A word of caution
73. Phase 2 studies of adenosine cardioplegia
74. Evidence for preconditioning by isoflurane in coronary artery bypass graft surgery
75. Cardioprotective effect of unstable angina prior to acute anterior myocardial infarction
76. Preinfarction angina as a major predictor of left ventricular function and long-term prognosis after first q-wave myocardial infarction
77. Preinfarction angina as a predictor of more rapid coronary thrombolysis in patients with acute myocardial infarction
78. Prospective temporal analysis of the onset of preinfarction angina versus outcome: An ancillary study in TIMI-9B
79. Evidence for the delayed effect in human ischemic preconditioning: Prospective multicenter study for preconditioning in acute myocardial infarction
80. Relationship between antecedent angina pectoris and short-term prognosis after thrombolytic therapy for acute myocardial infarction
81. Early spontaneous intermittent myocardial reperfusion during acute myocardial infarction is associated with augmented thrombogenic activity and less myocardial damage
82. Comparison of protective effects of preinfarction angina pectoris in acute myocardial infarction treated by thrombolysis versus primary coronary angioplasty with stenting
83. Changes in ischemic tolerance and effects of ischemic preconditioning in middle-aged rat hearts
84. The evolution of diabetic response to ischemia/reperfusion and preconditioning in isolated working rat hearts
85. The loss of pacing-induced preconditioning in atherosclerotic rabbits: Role of hypercholesterolaemia
86. Prevalence and mortality of acute myocardial infarction in patients with diabetes
87. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction
88. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
89. Myocardial infarction in diabetic vs non-diabetic subjects. Survival and infarct size following therapy with sulfonylureas
90. 2+ as a mediator of ischemic preconditioning
91. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease
92. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: A meta-analysis of randomised controlled trials
93. Captopril potentiates the myocardial infarct size-limiting effect of ischemic preconditioning through bradykinin B2 receptor activation
94. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: Results of a multicenter, randomized, placebo-controlled trial: The Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial
95. Cardioprotection by opening of the K(ATP) channel in unstable angina
96. Conscious rabbits become tolerant to multiple episodes of ischemic preconditioning
97. The anti-infarct effect of an adenosine A1-selective agonist is diminished after prolonged infusion as is the cardioprotective effect of ischaemic preconditioning in rabbit heart
98. Time course of delayed myocardial protection after transient adenosine A1-receptor activation in the rabbit